PSTV - Plus Therapeutics Inc
IEX Last Trade
1.42
0 0%
Share volume: 7,603
Last Updated: Fri 30 Aug 2024 07:10:40 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.42
0.00
0.00%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-07-21 | 2022-10-20 | 2023-02-23 | 2023-04-20 | 2023-08-14 | 2023-10-31 | 2024-03-05 | 2024-05-15 | |
| Assets | |||||||||
| Total Assets | 21.271 M | 23.104 M | 23.867 M | 15.638 M | 14.197 M | 13.278 M | 11.388 M | 5.621 M | |
| Current Assets | 18.889 M | 20.879 M | 21.817 M | 13.629 M | 12.364 M | 11.584 M | 9.834 M | 4.213 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 799.000 K | 540.000 K | 3.697 M | 906.000 K | 751.000 K | 487.000 K | 1.280 M | 1.312 M | |
| Short Term Investments | 799.000 K | 540.000 K | 3.697 M | 906.000 K | 751.000 K | 487.000 K | 1.280 M | 1.312 M | |
| Total Receivables | 0.000 | 73.000 K | 0.000 | 0.000 | 718.000 K | 91.000 K | 0.000 | 0.000 | |
| Current Cash | 18.090 M | 20.266 M | 18.120 M | 12.723 M | 10.895 M | 11.006 M | 8.554 M | 2.901 M | |
| Total Non-current Assets | 2.382 M | 2.225 M | 2.050 M | 2.009 M | 1.833 M | 1.694 M | 1.554 M | 1.408 M | |
| Property Plant Equipment | 1.560 M | 1.453 M | 1.324 M | 1.276 M | 1.143 M | 1.009 M | 906.000 K | 800.000 K | |
| Other Assets | 16.000 K | 12.000 K | 12.000 K | 12.000 K | 12.000 K | 32.000 K | 32.000 K | 32.000 K | |
| Intangible Assets | 131.000 K | 113.000 K | 94.000 K | 79.000 K | 64.000 K | 49.000 K | 42.000 K | 33.000 K | |
| Goodwill | 372.000 K | 372.000 K | 372.000 K | 372.000 K | 372.000 K | 372.000 K | 372.000 K | 372.000 K | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 21.271 M | 23.104 M | 23.867 M | 15.638 M | 14.197 M | 13.278 M | 11.388 M | 5.621 M | |
| Total liabilities | 11.592 M | 11.700 M | 17.422 M | 12.962 M | 11.535 M | 10.656 M | 12.736 M | 10.458 M | |
| Total current liabilities | 6.971 M | 7.420 M | 11.852 M | 12.796 M | 11.399 M | 10.538 M | 10.727 M | 10.399 M | |
| Accounts Payable | 0.000 | 0.000 | 8.364 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 0.000 | 0.000 | 1.643 M | 0.000 | 0.000 | 0.000 | 1.924 M | 0.000 | |
| Current long term debt | 1.608 M | 1.608 M | 1.608 M | 5.057 M | 4.709 M | 4.348 M | 3.976 M | 3.590 M | |
| Long term debt | 4.419 M | 4.108 M | 3.786 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 0.000 | 0.000 | 1.643 M | 0.000 | 0.000 | 0.000 | 1.924 M | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 9.679 M | 11.404 M | 6.445 M | 2.676 M | 2.662 M | 2.622 M | -1.348 M | -4.837 M | |
| Common stock | 22.255 M | 27.442 M | 33.817 M | 34.800 M | 2.509 M | 3.225 M | 4.509 M | 4.322 M | |
| Retained earnings | -456.308 M | -461.527 M | -467.185 M | -471.990 M | -473.472 M | -476.691 M | -480.501 M | -483.762 M |